Bristol Myers announces strategy to reach low- and middle-income countries

Bristol Myers Squibb announced ASPIRE, a 10-year strategy to advance access to our innovative treatments and help patients in low- and middle-income countries, or LMICs, gain access to potentially life-saving medicines. This strategy supports the company’s commitment to reach more than 200,000 patients in LMICs by 2033 with its innovative treatments. As part of ASPIRE, Bristol Myers Squibb is developing tailored strategies to increase affordability and availability of its medicines in LMICs. In low- and middle-income countries, to help improve the affordability of our medicines, the company introduced local brands of many of our innovative medicines to address affordability issues, expand access, and help reduce the time lag between the availability of our medicines in higher-income countries and lower-income countries. In 2023, BMS filed a total of 11 local brands of which five received regulatory approvals. BMS local brands are making an impact in countries like Thailand, which has the highest prevalence of beta thalassemia, by providing treatment options like Rojusna to help combat this widespread disease.